Home>Topics>Stocks>AstraZeneca PLC ADR

AstraZeneca PLC ADR AZN

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Fitch Downgrades AstraZenaca to 'A+'; Outlook Stable

      Headlines

      Fri, 21 Nov 2014

      the rating agency) LONDON, November 21 (Fitch) Fitch Ratings has downgraded UK-based pharmaceutical AstraZeneca PLC's ( AstraZeneca ) Long-term Issuer Default Rating (IDR) and senior unsecured rating to 'A+' from 'AA-'. The Outlook

    2. U.S. court overturns bid by India's Ranbaxy to block launch of rival generic drugs

      Headlines

      Thu, 20 Nov 2014

      Nov 20 (Reuters) - A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed.

    3. New Issue- AstraZeneca prices 750 mln euro 2021 bond

      Headlines

      Wed, 19 Nov 2014

      Underlying govt bond over midswaps, equivalent to 63.5 bp

    4. BRIEF-ADDvise Lab Solutions receives order from AstraZeneca of about SEK 2.4 mln

      Headlines

      Wed, 19 Nov 2014

      * Says receives order from AstraZeneca of about 2.4 million Swedish crowns

    5. UPDATE 3- AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer

      Headlines

      Tue, 18 Nov 2014

      * Investor day comes 8 days before Pfizer can resume pursuit

    6. BRIEF- AstraZeneca CEO says "hard to comment" on whether Pfizer will return

      Headlines

      Tue, 18 Nov 2014

      Nov 18 (Reuters) - AstraZeneca executives, speaking to reporters: * CEO says hard to comment on read-across from Pfizer/Merck cancer

    7. Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies

      Headlines

      Tue, 18 Nov 2014

      MUMBAI, Nov 18 (Reuters) - Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the Indian firm to launch copies of two drugs including AstraZeneca Plc's heartburn pill Nexium, court documents showed.

    8. Neil Woodford says belief in independent AstraZeneca "even stronger"

      Headlines

      Tue, 18 Nov 2014

      LONDON, Nov 18 (Reuters) - AstraZeneca shareholder Neil Woodford said on Tuesday his belief in the drugmaker's independent prospects were now "even stronger" as a result of the firm's strong pipeline of new products.

    9. AstraZeneca trumpets progress in cancer, other drugs

      Headlines

      Tue, 18 Nov 2014

      LONDON, Nov 18 (Reuters) - AstraZeneca , determined to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May, said it had made good progress in developing a pipeline of new drugs.

    10. Pfizer dampens Astra bid hopes with German Merck cancer deal

      Headlines

      Mon, 17 Nov 2014

      FRANKFURT/LONDON (Reuters) - Pfizer dampened investors' expectations of a renewed bid for AstraZeneca on Monday by signing a major cancer drug deal with Germany's Merck KGaA , reducing the U.S. firm's need for Astra's products.

    « Prev12345Next »
    Content Partners